[SCHEDULE 13G/A] PLUS THERAPEUTICS, Inc. SEC Filing
Schedule 13G/A (Amendment No. 1) filing for Plus Therapeutics, Inc. (NASDAQ: PSTV) discloses that The Hewlett Fund LP no longer holds any beneficial ownership in the company鈥檚 common stock.
Key facts:
- Date of event: 24 June 2025
- Reporting person: The Hewlett Fund LP (a New York limited partnership)
- Shares beneficially owned: 0.00
- Percent of class: 0%
- Voting & dispositive power: 0 shares sole or shared
- Reason for filing: Ownership has fallen to (or remains) 5 percent or less of outstanding common stock, triggering a final amendment under Rule 13d-2.
This amendment replaces an earlier Schedule 13G in which the same fund reported an ownership position exceeding the 5 % reporting threshold. By certifying zero shares, The Hewlett Fund LP confirms that it has fully exited its previously disclosed stake and no longer seeks to influence control of Plus Therapeutics. Apart from this ownership update, the filing contains no financial performance data, strategic commentary or transactional details.
La dichiarazione Schedule 13G/A (Emendamento n. 1) per Plus Therapeutics, Inc. (NASDAQ: PSTV) comunica che The Hewlett Fund LP non detiene pi霉 alcuna propriet脿 beneficiaria delle azioni ordinarie della societ脿.
Fatti principali:
- Data dell'evento: 24 giugno 2025
- Persona che presenta la dichiarazione: The Hewlett Fund LP (una societ脿 in accomandita semplice di New York)
- Azioni detenute beneficiariamente: 0,00
- Percentuale della classe: 0%
- Potere di voto e dispositive: 0 azioni in modo esclusivo o condiviso
- Motivo della presentazione: La propriet脿 猫 scesa a (o rimane) pari o inferiore al 5% delle azioni ordinarie in circolazione, attivando un emendamento finale ai sensi della Regola 13d-2.
Questo emendamento sostituisce un precedente Schedule 13G in cui lo stesso fondo aveva dichiarato una posizione di propriet脿 superiore alla soglia di segnalazione del 5%. Certificando zero azioni, The Hewlett Fund LP conferma di aver completamente ceduto la sua partecipazione precedentemente dichiarata e di non cercare pi霉 di influenzare il controllo di Plus Therapeutics. A parte questo aggiornamento sulla propriet脿, la dichiarazione non contiene dati sulle performance finanziarie, commenti strategici o dettagli sulle transazioni.
La presentaci贸n Schedule 13G/A (Enmienda No. 1) para Plus Therapeutics, Inc. (NASDAQ: PSTV) revela que The Hewlett Fund LP ya no posee ninguna propiedad beneficiaria en las acciones comunes de la empresa.
Datos clave:
- Fecha del evento: 24 de junio de 2025
- Persona que reporta: The Hewlett Fund LP (una sociedad limitada de Nueva York)
- Acciones pose铆das beneficiosamente: 0.00
- Porcentaje de la clase: 0%
- Poder de voto y disposici贸n: 0 acciones en propiedad exclusiva o compartida
- Raz贸n de la presentaci贸n: La propiedad ha ca铆do a (o permanece) 5 por ciento o menos de las acciones comunes en circulaci贸n, lo que activa una enmienda final bajo la Regla 13d-2.
Esta enmienda reemplaza un Schedule 13G anterior en el que el mismo fondo report贸 una posici贸n accionaria superior al umbral de reporte del 5%. Al certificar cero acciones, The Hewlett Fund LP confirma que ha salido completamente de su participaci贸n previamente declarada y que ya no busca influir en el control de Plus Therapeutics. Aparte de esta actualizaci贸n de propiedad, la presentaci贸n no contiene datos de rendimiento financiero, comentarios estrat茅gicos ni detalles de transacciones.
Plus Therapeutics, Inc. (NASDAQ: PSTV)鞐� 雽�頃� Schedule 13G/A (靾橃爼 鞝�1順�) 鞝滌稖鞚赌 The Hewlett Fund LP臧� 雿� 鞚挫儊 須岇偓鞚� 氤错喌欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 瓿店皽頃╇媹雼�.
欤检殧 雮挫毄:
- 靷贝 鞚检瀽: 2025雲� 6鞗� 24鞚�
- 氤搓碃鞛�: The Hewlett Fund LP (雺挫殨 鞙犿暅 頃╈瀽須岇偓)
- 鞁れ 靻岇湢 欤检嫕 靾�: 0.00
- 歆�攵� 牍勳湪: 0%
- 鞚橁舶甓� 氚� 觳橂秳 甓岉暅: 雼弲 霕愲姅 瓿惦彊 0欤�
- 鞝滌稖 靷湢: 靻岇湢 歆�攵勳澊 (霕愲姅 瓿勳啀) 5% 鞚错晿搿� 霒柎鞝� Rule 13d-2鞐� 霐半ジ 斓滌 靾橃爼 鞝滌稖鞚� 鞖旉惮霅�.
鞚� 靾橃爼 鞝滌稖鞚赌 霃欖澕頃� 韼�霌滉皜 5% 氤搓碃 旮办鞚� 齑堦臣頃橂姅 靻岇湢 歆�攵勳潉 鞁犼碃頄堧崢 鞚挫爠 Schedule 13G毳� 雽�觳错暕雼堧嫟. 0欤茧ゼ 鞚胳頃溂搿滌崹 The Hewlett Fund LP電� 鞚挫爠鞐� 瓿店皽頃� 歆�攵勳潉 鞕勳爠頌� 觳橂秳頄堨溂氅� 雿� 鞚挫儊 Plus Therapeutics鞚� 瓴届榿甓岇棎 鞓來枼鞚� 氙胳箻霠� 頃橃 鞎婌潓鞚� 頇曥澑頃╇媹雼�. 鞚� 靻岇湢甓� 鞐呺嵃鞚错姼 鞕胳棎電� 鞝滌稖靹滌棎 鞛 靹标臣 雿办澊韯�, 鞝勲灥鞝� 雲柬弶 霕愲姅 瓯半灅 雮挫棴鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
D茅p么t du Schedule 13G/A (Amendement n掳1) pour Plus Therapeutics, Inc. (NASDAQ : PSTV) r茅v猫le que The Hewlett Fund LP ne d茅tient plus aucune propri茅t茅 b茅n茅ficiaire dans les actions ordinaires de la soci茅t茅.
Faits cl茅s :
- Date de l'茅v茅nement : 24 juin 2025
- Personne d茅clarant : The Hewlett Fund LP (une soci茅t茅 en commandite de l'脡tat de New York)
- Actions d茅tenues b茅n茅ficiaires : 0,00
- Pourcentage de la cat茅gorie : 0%
- Pouvoir de vote et de disposition : 0 actions en propri茅t茅 exclusive ou partag茅e
- Motif du d茅p么t : La propri茅t茅 est tomb茅e 脿 (ou reste) 5 % ou moins du capital social en circulation, d茅clenchant un amendement final en vertu de la r猫gle 13d-2.
Cet amendement remplace un pr茅c茅dent Schedule 13G dans lequel le m锚me fonds avait d茅clar茅 une position de propri茅t茅 d茅passant le seuil de d茅claration de 5 %. En certifiant z茅ro action, The Hewlett Fund LP confirme avoir enti猫rement c茅d茅 sa participation pr茅c茅demment divulgu茅e et ne cherche plus 脿 influencer le contr么le de Plus Therapeutics. En dehors de cette mise 脿 jour de propri茅t茅, le d茅p么t ne contient aucune donn茅e financi猫re, commentaire strat茅gique ou d茅tail transactionnel.
Schedule 13G/A (脛nderung Nr. 1) Einreichung f眉r Plus Therapeutics, Inc. (NASDAQ: PSTV) gibt bekannt, dass The Hewlett Fund LP keine wirtschaftlichen Eigentumsrechte an den Stammaktien des Unternehmens mehr h盲lt.
Wesentliche Fakten:
- Datum des Ereignisses: 24. Juni 2025
- Meldende Person: The Hewlett Fund LP (eine Limited Partnership in New York)
- Wirtschaftlich gehaltene Aktien: 0,00
- Prozentsatz der Aktienklasse: 0%
- Stimm- und Verf眉gungsgewalt: 0 Aktien allein oder gemeinsam
- Grund f眉r die Einreichung: Der Besitz ist auf (oder bleibt) 5 Prozent oder weniger der ausstehenden Stammaktien gefallen, was eine endg眉ltige 脛nderung gem盲脽 Regel 13d-2 ausl枚st.
Diese 脛nderung ersetzt ein fr眉heres Schedule 13G, in dem derselbe Fonds eine Besitzposition 眉ber der 5%-Meldegrenze angegeben hatte. Durch die Zertifizierung von null Aktien best盲tigt The Hewlett Fund LP, dass es seine zuvor offen gelegte Beteiligung vollst盲ndig ver盲u脽ert hat und nicht mehr versucht, die Kontrolle 眉ber Plus Therapeutics zu beeinflussen. Abgesehen von diesem Eigentumsupdate enth盲lt die Einreichung keine Finanzdaten, strategische Kommentare oder Transaktionsdetails.
- None.
- The Hewlett Fund LP now reports 0% ownership, signalling a complete exit and potential loss of institutional support for PSTV.
Insights
TL;DR: Large holder exits PSTV, eliminating prior >5 % stake; modest negative signal.
The Hewlett Fund LP鈥檚 complete divestiture reduces institutional ownership and may slightly weaken the demand side of PSTV鈥檚 float. Because the fund had previously crossed the 5 % threshold, its withdrawal suggests it no longer sees a compelling near-term upside. While not dilutive, the absence of a committed shareholder can diminish market confidence and increase share-price volatility, especially for a micro-cap biotech reliant on supportive capital bases. No new strategic investors are identified to offset this exit, so the filing leans negative for sentiment rather than fundamentals.
TL;DR: Governance neutral 鈥� fund鈥檚 sale removes potential influence over PSTV鈥檚 decisions.
With ownership at 0 %, The Hewlett Fund LP relinquishes any voting or activist leverage. This simplifies PSTV鈥檚 shareholder map and lowers the risk of coordinated control campaigns flagged under 13D rules. From a governance standpoint, management faces fewer constraints from this particular investor but might need to broaden investor outreach to maintain diversified support. The event is formally material only because it crosses the statutory 5 % threshold; operational impact is limited.
La dichiarazione Schedule 13G/A (Emendamento n. 1) per Plus Therapeutics, Inc. (NASDAQ: PSTV) comunica che The Hewlett Fund LP non detiene pi霉 alcuna propriet脿 beneficiaria delle azioni ordinarie della societ脿.
Fatti principali:
- Data dell'evento: 24 giugno 2025
- Persona che presenta la dichiarazione: The Hewlett Fund LP (una societ脿 in accomandita semplice di New York)
- Azioni detenute beneficiariamente: 0,00
- Percentuale della classe: 0%
- Potere di voto e dispositive: 0 azioni in modo esclusivo o condiviso
- Motivo della presentazione: La propriet脿 猫 scesa a (o rimane) pari o inferiore al 5% delle azioni ordinarie in circolazione, attivando un emendamento finale ai sensi della Regola 13d-2.
Questo emendamento sostituisce un precedente Schedule 13G in cui lo stesso fondo aveva dichiarato una posizione di propriet脿 superiore alla soglia di segnalazione del 5%. Certificando zero azioni, The Hewlett Fund LP conferma di aver completamente ceduto la sua partecipazione precedentemente dichiarata e di non cercare pi霉 di influenzare il controllo di Plus Therapeutics. A parte questo aggiornamento sulla propriet脿, la dichiarazione non contiene dati sulle performance finanziarie, commenti strategici o dettagli sulle transazioni.
La presentaci贸n Schedule 13G/A (Enmienda No. 1) para Plus Therapeutics, Inc. (NASDAQ: PSTV) revela que The Hewlett Fund LP ya no posee ninguna propiedad beneficiaria en las acciones comunes de la empresa.
Datos clave:
- Fecha del evento: 24 de junio de 2025
- Persona que reporta: The Hewlett Fund LP (una sociedad limitada de Nueva York)
- Acciones pose铆das beneficiosamente: 0.00
- Porcentaje de la clase: 0%
- Poder de voto y disposici贸n: 0 acciones en propiedad exclusiva o compartida
- Raz贸n de la presentaci贸n: La propiedad ha ca铆do a (o permanece) 5 por ciento o menos de las acciones comunes en circulaci贸n, lo que activa una enmienda final bajo la Regla 13d-2.
Esta enmienda reemplaza un Schedule 13G anterior en el que el mismo fondo report贸 una posici贸n accionaria superior al umbral de reporte del 5%. Al certificar cero acciones, The Hewlett Fund LP confirma que ha salido completamente de su participaci贸n previamente declarada y que ya no busca influir en el control de Plus Therapeutics. Aparte de esta actualizaci贸n de propiedad, la presentaci贸n no contiene datos de rendimiento financiero, comentarios estrat茅gicos ni detalles de transacciones.
Plus Therapeutics, Inc. (NASDAQ: PSTV)鞐� 雽�頃� Schedule 13G/A (靾橃爼 鞝�1順�) 鞝滌稖鞚赌 The Hewlett Fund LP臧� 雿� 鞚挫儊 須岇偓鞚� 氤错喌欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 瓿店皽頃╇媹雼�.
欤检殧 雮挫毄:
- 靷贝 鞚检瀽: 2025雲� 6鞗� 24鞚�
- 氤搓碃鞛�: The Hewlett Fund LP (雺挫殨 鞙犿暅 頃╈瀽須岇偓)
- 鞁れ 靻岇湢 欤检嫕 靾�: 0.00
- 歆�攵� 牍勳湪: 0%
- 鞚橁舶甓� 氚� 觳橂秳 甓岉暅: 雼弲 霕愲姅 瓿惦彊 0欤�
- 鞝滌稖 靷湢: 靻岇湢 歆�攵勳澊 (霕愲姅 瓿勳啀) 5% 鞚错晿搿� 霒柎鞝� Rule 13d-2鞐� 霐半ジ 斓滌 靾橃爼 鞝滌稖鞚� 鞖旉惮霅�.
鞚� 靾橃爼 鞝滌稖鞚赌 霃欖澕頃� 韼�霌滉皜 5% 氤搓碃 旮办鞚� 齑堦臣頃橂姅 靻岇湢 歆�攵勳潉 鞁犼碃頄堧崢 鞚挫爠 Schedule 13G毳� 雽�觳错暕雼堧嫟. 0欤茧ゼ 鞚胳頃溂搿滌崹 The Hewlett Fund LP電� 鞚挫爠鞐� 瓿店皽頃� 歆�攵勳潉 鞕勳爠頌� 觳橂秳頄堨溂氅� 雿� 鞚挫儊 Plus Therapeutics鞚� 瓴届榿甓岇棎 鞓來枼鞚� 氙胳箻霠� 頃橃 鞎婌潓鞚� 頇曥澑頃╇媹雼�. 鞚� 靻岇湢甓� 鞐呺嵃鞚错姼 鞕胳棎電� 鞝滌稖靹滌棎 鞛 靹标臣 雿办澊韯�, 鞝勲灥鞝� 雲柬弶 霕愲姅 瓯半灅 雮挫棴鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
D茅p么t du Schedule 13G/A (Amendement n掳1) pour Plus Therapeutics, Inc. (NASDAQ : PSTV) r茅v猫le que The Hewlett Fund LP ne d茅tient plus aucune propri茅t茅 b茅n茅ficiaire dans les actions ordinaires de la soci茅t茅.
Faits cl茅s :
- Date de l'茅v茅nement : 24 juin 2025
- Personne d茅clarant : The Hewlett Fund LP (une soci茅t茅 en commandite de l'脡tat de New York)
- Actions d茅tenues b茅n茅ficiaires : 0,00
- Pourcentage de la cat茅gorie : 0%
- Pouvoir de vote et de disposition : 0 actions en propri茅t茅 exclusive ou partag茅e
- Motif du d茅p么t : La propri茅t茅 est tomb茅e 脿 (ou reste) 5 % ou moins du capital social en circulation, d茅clenchant un amendement final en vertu de la r猫gle 13d-2.
Cet amendement remplace un pr茅c茅dent Schedule 13G dans lequel le m锚me fonds avait d茅clar茅 une position de propri茅t茅 d茅passant le seuil de d茅claration de 5 %. En certifiant z茅ro action, The Hewlett Fund LP confirme avoir enti猫rement c茅d茅 sa participation pr茅c茅demment divulgu茅e et ne cherche plus 脿 influencer le contr么le de Plus Therapeutics. En dehors de cette mise 脿 jour de propri茅t茅, le d茅p么t ne contient aucune donn茅e financi猫re, commentaire strat茅gique ou d茅tail transactionnel.
Schedule 13G/A (脛nderung Nr. 1) Einreichung f眉r Plus Therapeutics, Inc. (NASDAQ: PSTV) gibt bekannt, dass The Hewlett Fund LP keine wirtschaftlichen Eigentumsrechte an den Stammaktien des Unternehmens mehr h盲lt.
Wesentliche Fakten:
- Datum des Ereignisses: 24. Juni 2025
- Meldende Person: The Hewlett Fund LP (eine Limited Partnership in New York)
- Wirtschaftlich gehaltene Aktien: 0,00
- Prozentsatz der Aktienklasse: 0%
- Stimm- und Verf眉gungsgewalt: 0 Aktien allein oder gemeinsam
- Grund f眉r die Einreichung: Der Besitz ist auf (oder bleibt) 5 Prozent oder weniger der ausstehenden Stammaktien gefallen, was eine endg眉ltige 脛nderung gem盲脽 Regel 13d-2 ausl枚st.
Diese 脛nderung ersetzt ein fr眉heres Schedule 13G, in dem derselbe Fonds eine Besitzposition 眉ber der 5%-Meldegrenze angegeben hatte. Durch die Zertifizierung von null Aktien best盲tigt The Hewlett Fund LP, dass es seine zuvor offen gelegte Beteiligung vollst盲ndig ver盲u脽ert hat und nicht mehr versucht, die Kontrolle 眉ber Plus Therapeutics zu beeinflussen. Abgesehen von diesem Eigentumsupdate enth盲lt die Einreichung keine Finanzdaten, strategische Kommentare oder Transaktionsdetails.
FAQ
Why did The Hewlett Fund LP file a Schedule 13G/A for PSTV?
How many Plus Therapeutics (PSTV) shares does The Hewlett Fund LP currently own?
What is the effective date of The Hewlett Fund LP's ownership change?
Does the filing indicate any voting or dispositive power retained by The Hewlett Fund LP?
Is this Schedule 13G/A likely to impact Plus Therapeutics鈥� control structure?
